Gasbarri A, Introini-Collison I B, Packard M G, Pacitti C, McGaugh J L
Center for the Neurobiology of Learning and Memory, University of California, Irvine 92717-3800.
Brain Res. 1993 Nov 5;627(1):72-8. doi: 10.1016/0006-8993(93)90750-h.
These experiments examined the interaction between muscarinic cholinergic and dopaminergic systems in the modulation of memory storage. Male CD1 mice (25-30 g) were trained in an inhibitory avoidance (IA) and a Y-maze discrimination (YMD) task. The first experiment examined the dose-response effects, on retention, of agonists and antagonists specific for either D1- or D2-receptors. Immediately posttraining mice were given i.p. injections of saline, the D1-receptor agonists SKF 38393 (3.0, 10.0 or 30.0 mg/kg) or SKF 77434 (3.0, 10.0 or 30.0 mg/kg), the D1-receptor antagonist SCH 23390 (0.03, 0.1, or 1.0 mg/kg), the D2-receptor agonist quinpirole (0.3, 1.0 or 3.0 mg/kg) or the D2-receptor antagonist sulpiride (3.0, 10.0, 30.0 or 100.0 mg/kg). Retention was tested 48 h later. The drugs affecting D1-receptors did not affect retention. In contrast, in both tasks quinpirole enhanced retention and sulpiride impaired retention. In the IA task, quinpirole (3.0 mg/kg) blocked the retention impairing effects of the muscarinic cholinergic antagonist atropine (10.0 mg/kg), and sulpiride (3.0, 10.0, 30.0 or 100.0 mg/kg) significantly attenuated the memory enhancing effects of the muscarinic cholinergic agonist oxotremorine (35.0 or 70.0 micrograms/kg). D1-receptor agents did not modify the effects of either atropine or oxotremorine on retention of the IA response. These findings suggest that the effects of cholinergic muscarinic agents on retention of the IA response are mediated by influences involving D2-dopaminergic mechanisms. In the YMD task, atropine (10.0 mg/kg) blocked the memory-enhancing effects of quinpirole (3.0 mg/kg) and oxotremorine (35.0 or 70.0 micrograms/kg) attenuated the memory impairing effect of sulpiride (3.0, 10.0, 30.0 or 100.0 mg/kg).(ABSTRACT TRUNCATED AT 250 WORDS)
这些实验研究了毒蕈碱型胆碱能系统与多巴胺能系统在记忆存储调节中的相互作用。雄性CD1小鼠(25 - 30克)接受抑制性回避(IA)和Y迷宫辨别(YMD)任务训练。第一个实验检测了D1或D2受体特异性激动剂和拮抗剂对记忆保持的剂量反应效应。训练后立即给小鼠腹腔注射生理盐水、D1受体激动剂SKF 38393(3.0、10.0或30.0毫克/千克)或SKF 77434(3.0、10.0或30.0毫克/千克)、D1受体拮抗剂SCH 23390(0.03、0.1或1.0毫克/千克)、D2受体激动剂喹吡罗(0.3、1.0或3.0毫克/千克)或D2受体拮抗剂舒必利(3.0、10.0、30.0或100.0毫克/千克)。48小时后测试记忆保持情况。影响D1受体的药物不影响记忆保持。相反,在两个任务中喹吡罗增强记忆保持,舒必利损害记忆保持。在IA任务中,喹吡罗(3.0毫克/千克)阻断了毒蕈碱型胆碱能拮抗剂阿托品(10.0毫克/千克)对记忆保持的损害作用,舒必利(3.0、10.0、30.0或100.0毫克/千克)显著减弱了毒蕈碱型胆碱能激动剂氧化震颤素(35.0或70.0微克/千克)的记忆增强作用。D1受体药物不改变阿托品或氧化震颤素对IA反应记忆保持的影响。这些发现表明,胆碱能毒蕈碱药物对IA反应记忆保持的影响是由涉及D2 - 多巴胺能机制的影响介导的。在YMD任务中,阿托品(10.0毫克/千克)阻断了喹吡罗(3.0毫克/千克)的记忆增强作用,氧化震颤素(35.0或70.0微克/千克)减弱了舒必利(3.0、10.0、30.0或100.0毫克/千克)的记忆损害作用。(摘要截断于250字)